Immunome 8-K Signals Executive/Comp Changes on Jan 2, 2024
Ticker: IMNM · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $40,000, $15,000, $5,000, $270,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**Immunome filed an 8-K on Jan 2, 2024, indicating executive or compensation changes; watch for details.**
AI Summary
Immunome, Inc. filed an 8-K on January 2, 2024, to report an event related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'. This filing indicates changes in key personnel or their compensation structures, which is crucial for investors as leadership stability and executive incentives can significantly impact a company's strategic direction and financial performance. Shareholders should monitor subsequent filings for specific details on who departed or was appointed and the terms of any new compensatory arrangements.
Why It Matters
Changes in executive leadership or compensation can signal shifts in company strategy or financial health, directly impacting investor confidence and future stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership or compensation can introduce uncertainty, but the specific impact depends on the nature of the changes, which are not yet detailed in this filing.
Analyst Insight
A smart investor would monitor Immunome's subsequent filings closely for specific details regarding the executive and compensation changes, as these will provide clarity on the company's strategic direction and potential impact on its future performance.
Key Players & Entities
- Immunome, Inc. (company) — the registrant filing the 8-K
- January 2, 2024 (date) — date of the earliest event reported and filing date
- 001-39580 (string) — Commission File Number for Immunome, Inc.
- IMNM (string) — trading symbol for Immunome, Inc. Common Stock
- The Nasdaq Capital Market (string) — exchange where Immunome, Inc. Common Stock is registered
Forward-Looking Statements
- Immunome, Inc. will file a subsequent 8-K or 10-K/Q detailing the specific personnel changes or compensation arrangements. (Immunome, Inc.) — high confidence, target: Q1 2024
- The market will react to the specific details of the executive changes once they are disclosed. (IMNM stock price) — medium confidence, target: Upon disclosure
FAQ
What specific event did Immunome, Inc. report in this 8-K filing on January 2, 2024?
Immunome, Inc. reported an event under Item 5.02, titled 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' on January 2, 2024.
What is the trading symbol and the exchange where Immunome, Inc.'s common stock is registered?
Immunome, Inc.'s common stock trades under the symbol IMNM on The Nasdaq Capital Market.
What is the business address and phone number of Immunome, Inc. as stated in the filing?
The business address for Immunome, Inc. is 665 Stockton Drive, Suite 300, Exton, Pennsylvania, 19342, and their telephone number is (610) 321-3700.
What is Immunome, Inc.'s state of incorporation and IRS Employer Identification Number?
Immunome, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 77-0694340.
Does Immunome, Inc. indicate if it is an emerging growth company in this filing?
The filing includes a checkbox to 'Indicate by check mark whether the registrant is an emerging growth company,' but the provided text does not show whether the box is checked or unchecked, so it does not explicitly state if Immunome, Inc. is an emerging growth company.
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-01-02 08:05:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
- $40,000 — receive (i) an annual cash retainer of $40,000 for service as a member of the Board, (
- $15,000 — e Board, (ii) an annual cash retainer of$15,000 for service as Chair of the Audit Commi
- $5,000 — tee, and (iii)an annual cash retainer of$5,000 for service as a member of the Nominati
- $270,000 — aggregate Black-Scholes option value of $270,000, which vests quarterly over a three-yea
- $135,000 — aggregate Black-Scholes option value of $135,000 on the date of each annual meeting of s
Filing Documents
- tm2334002d1_8k.htm (8-K) — 28KB
- 0001104659-24-000121.txt ( ) — 197KB
- immu-20240102.xsd (EX-101.SCH) — 3KB
- immu-20240102_lab.xml (EX-101.LAB) — 33KB
- immu-20240102_pre.xml (EX-101.PRE) — 22KB
- tm2334002d1_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IMMUNOME, INC. Date: January 2, 2024 By: /s/ Clay Siegall Clay Siegall, Ph.D. President and Chief Executive Officer